Dilbaz S, Caliskan E, Dilbaz B, Kahraman B G
Department of Obstetrics and Gynecology, SSK Ankara Maternity and Women's Health Teaching Hospital, Ankara, Turkey.
Eur J Contracept Reprod Health Care. 2004 Mar;9(1):11-5. doi: 10.1080/13625180410001696232.
To determine the efficacy of an application regimen of low-dose frequent misoprostol for second-trimester pregnancy termination.
A total of 250 women between 12 and 20 weeks of gestation who were scheduled for second-trimester pregnancy termination received 200 microg vaginal misoprostol followed by 100 microg oral misoprostol every 2 h until expulsion of the fetus. Mechanical cervical dilatation with a 16-French Foley balloon catheter was performed if no cervical dilatation was observed after 24 h. The main outcome measures were the delivery rate within 24 h and the factors influencing the interval between the onset of induction and abortion. Secondary outcome measures were the side-effects of the regimen and the total misoprostol dose required.
With application of this protocol, 245 women (98%) delivered within 24 h of induction. The mean (+/-standard deviation) misoprostol dose used was 728+/-297 microg (200-2100 microg). Cox regression analysis revealed that vaginal spotting or nulliparity do not effect the induction-abortion time. On the other hand, using this regimen induction to abortion time tends to be longer in the presence of live fetuses (odds ratio (OR) = 0.45; confidence interval (CI) =0.2-0.8; p=0.008) and pregnancies with gestational age > 16 weeks (OR= 0.59; CI = 0.4-0.8; p= 0.003) when compared with cases of in utero death and pregnancies with a gestational age of 12-13 weeks, respectively. Twenty-seven women (10.8%) experienced one or more side-effects attributable to misoprostol.
The 100-microg oral misoprostol every 2 h following 200 microg vaginal misoprostol is a highly effective protocol for inducing abortion at 12-20 weeks of pregnancy. Cases with live fetuses or pregnancies with older gestational age (> 16 weeks) deliver in a longer time period.
确定低剂量频繁使用米索前列醇的用药方案用于孕中期终止妊娠的疗效。
共有250名妊娠12至20周且计划终止孕中期妊娠的妇女,先接受200微克阴道米索前列醇,之后每2小时口服100微克米索前列醇,直至胎儿排出。若24小时后未观察到宫颈扩张,则使用16号法国Foley球囊导管进行机械性宫颈扩张。主要结局指标为24小时内的分娩率以及影响引产开始至流产间隔时间的因素。次要结局指标为该用药方案的副作用以及所需米索前列醇的总剂量。
采用此方案,245名妇女(98%)在引产24小时内分娩。使用的米索前列醇平均(±标准差)剂量为728±297微克(200 - 2100微克)。Cox回归分析显示,阴道点滴出血或初产状态不影响引产至流产时间。另一方面,与宫内死亡病例和孕龄为12 - 13周的妊娠相比,采用此方案时,活胎妊娠(比值比(OR)= 0.45;置信区间(CI)= 0.2 - 0.8;p = 0.008)以及孕龄> 16周的妊娠(OR = 0.59;CI = 0.4 - 0.8;p = 0.003)引产至流产时间往往更长。27名妇女(10.8%)出现一种或多种归因于米索前列醇的副作用。
在200微克阴道米索前列醇后每2小时口服100微克米索前列醇是用于妊娠12至20周引产的高效方案。活胎妊娠或孕龄较大(> 16周)的妊娠分娩时间较长。